UK: A recent systematic review published in Clinical Rheumatology has investigated the potential of botulinum toxin (BTX) as ...

The following is a summary of “Trigeminal neuralgia improvement following Transcutaneous Electrical Nerve Stimulation (TENS): ...

Patients participated in once-a-month 2-hour classes performed by healthcare professionals. VAS pain, WOMAC (Likert Scale) and overall satisfaction with provided medical aid score (0-100 mm VAS scale) ...

Bimekizumab (Bimzelx; UCB Pharma) was approved by the FDA to treat psoriatic arthritis (PsA) on September 23, 2024, based on ...

Outcome Primary outcomes were visual analogue scale (VAS) pain score change and withdrawal from the study due to lack of efficacy. Results 9 of the patients assessed for eligibility declined to ...

Placebo was sham ultrasound and light application of a non-therapeutic gel, followed by no treatment. Primary outcomes were pain measured by visual analogue scale and patient global change. Secondary ...

The Visual Analogue Scale for Irritable Bowel Syndrome (VAS-IBS) questionnaire was designed to measure the treatment response of symptoms and well-being in patients suffering from IBS. Methods ...

visual analogue pain scale 2, 4, 8, 16, 24 'Mean MAS score' decreased in all botulinum toxin groups at week 8 compared with placebo. Improved VAS score compared with placebo at weeks 8 and 24.

Measurements Outcomes were assessed at baseline and at 3, 6 and 9 months after randomisation. The primary outcome measure was the Impairment level Sum Score—Restricted Version (ISS-RV), consisting of ...

Botulinum toxin (BTX), widely known for its cosmetic and neurological applications, is emerging as a potential treatment for Raynaud’s phenomenon (RP), particularly when secondary to scleroderma.